05.23.08
DOR BioPharma has opened a new corporate office in the UK. The new office gives DOR a presence in the EU to better facilitate the Named Patient Access program that will be administered by IDIS, also based in the UK. Serving as the company's official interface for regulatory interactions within the EU, the office will operate as DOR BioPharma UK Ltd. and will be located at: BioPark, Broadwater Road, Welwyn Garden City, Hertfordshire.
"The new DOR UK office gives us a multinational presence that we have not previously had," said Christopher J. Schaber, Ph.D., President and CEO of DOR. "This new office will aid us in achieving our strategic vision of making orBec available to patients throughout Europe through our Named Patient Access programs while we conduct our confirmatory Phase III clinical trial. It also has the potential to facilitate the conduct of new clinical trials in Europe as well as to provide support to European business relationships in the future."
"The new DOR UK office gives us a multinational presence that we have not previously had," said Christopher J. Schaber, Ph.D., President and CEO of DOR. "This new office will aid us in achieving our strategic vision of making orBec available to patients throughout Europe through our Named Patient Access programs while we conduct our confirmatory Phase III clinical trial. It also has the potential to facilitate the conduct of new clinical trials in Europe as well as to provide support to European business relationships in the future."